{"id":4740,"date":"2025-10-07T12:35:42","date_gmt":"2025-10-07T09:35:42","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4740"},"modified":"2025-11-03T20:18:48","modified_gmt":"2025-11-03T17:18:48","slug":"new-data-presented-on-duvyzat-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-2025-world-muscle-society-congress","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/new-data-presented-on-duvyzat-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-2025-world-muscle-society-congress\/","title":{"rendered":"Nouvelles donn\u00e9es pr\u00e9sent\u00e9es sur le Duvyzat (Givinostat) pour le traitement de la dystrophie musculaire de Duchenne au congr\u00e8s 2025 de la World Muscle Society"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Italfarmaco a annonc\u00e9 que des donn\u00e9es suppl\u00e9mentaires sur le givinostat pour le traitement de la dystrophie musculaire de Duchenne (DMD) sont pr\u00e9sent\u00e9es lors du 30e Congr\u00e8s international annuel de la World Muscle Society (WMS) qui se tiendra du 7 au 11 octobre \u00e0 Vienne, en Autriche.<\/strong> Les pr\u00e9sentations par affiches soulignent la s\u00e9curit\u00e9 \u00e0 long terme du givinostat chez les patients atteints de DMD, explorent l&#039;efficacit\u00e9 en fonction de l&#039;\u00e2ge dans une analyse post-hoc de l&#039;\u00e9tude pivot EPIDYS et fournissent une caract\u00e9risation d\u00e9taill\u00e9e des \u00e9v\u00e9nements ind\u00e9sirables gastro-intestinaux observ\u00e9s dans cette \u00e9tude de phase 3. &lt; <a href=\"https:\/\/dmdwarrior.com\/fr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"3957\" rel=\"noreferrer noopener\">Qu&#039;est-ce que Duvyzat (Givinostat) ?<\/a> &gt;&gt;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces donn\u00e9es issues d&#039;\u00e9tudes sponsoris\u00e9es par Italfarmaco pr\u00e9sent\u00e9es au congr\u00e8s WMS 2025 comprennent :<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>651P Innocuit\u00e9 \u00e0 long terme du givinostat chez les patients atteints de dystrophie musculaire de Duchenne\u00a0: r\u00e9sultats d&#039;une \u00e9tude d&#039;extension ouverte<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;\u00e9tude \u00e0 long terme en cours sur le givinostat chez les gar\u00e7ons atteints de DMD continue de fournir des informations sur la s\u00e9curit\u00e9 et la tol\u00e9rance du traitement, avec des r\u00e9sultats coh\u00e9rents avec ceux d&#039;\u00e9tudes ant\u00e9rieures de plus courte dur\u00e9e. Certains patients prennent d\u00e9sormais du givinostat depuis plus de huit ans au total, au cours de plusieurs \u00e9tudes et phases d&#039;extension.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>684VP Efficacit\u00e9 du givinostat selon l&#039;\u00e2ge (6-7 ans et &gt;7 ans)\u00a0: une analyse post-hoc de l&#039;\u00e9tude EPIDYS<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les \u00e9valuations de base de l\u2019\u00e9tude ont fourni des informations cl\u00e9s sur la fonction physique des gar\u00e7ons atteints de DMD dans diff\u00e9rents groupes d\u2019\u00e2ge.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>688VP Caract\u00e9risation des effets ind\u00e9sirables gastro-intestinaux d&#039;int\u00e9r\u00eat issus d&#039;une \u00e9tude de phase 3 sur le givinostat chez des patients atteints de dystrophie musculaire de Duchenne<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;\u00e9tude continue de surveiller les \u00e9v\u00e9nements gastro-intestinaux chez les participants. La plupart des \u00e9v\u00e9nements rapport\u00e9s \u00e9taient d&#039;intensit\u00e9 l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e et se r\u00e9sorbaient sans n\u00e9cessiter l&#039;arr\u00eat du traitement. Ces r\u00e9sultats fournissent un contexte important pour comprendre la s\u00e9curit\u00e9 et la tol\u00e9rance globales du traitement \u00e0 long terme.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Italfarmaco announced that additional data on givinostat for the treatment of Duchenne muscular dystrophy (DMD) are being presented at the 30th annual International Congress of the World Muscle Society (WMS) held October 7-11 in Vienna, Austria. Poster presentations highlight the long-term safety of givinostat in patients with DMD, explore efficacy by age in a post [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4741,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[46,47,311],"class_list":["post-4740","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duvyzat","tag-givinostat","tag-italfarmaco"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4740"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4740\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4741"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}